Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND Study of TMB-001 in X-linked or ARCI Ichthyosis
2022-000459-35Phase 3Completed
- Sponsor
- Timber Pharmaceuticals, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ichthyosis and autosomal recessive congenital ichthyosis (ARCI) comparing TMB-001 0.05% with Vehicle control (2 arms). Started Jun 2022; status: completed.
02
Drugs
TMB-001
03
Conditions
ichthyosisautosomal recessive congenital ichthyosis (ARCI)
Beyond the preview
Go deeper on 2022-000459-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000459-35.